NEUROSEARCH

**Investor News**

**NeuroSearch to make a presentation at the Swedish-American Life Science Summit 2010 in Stockholm**

*Copenhagen, 27 September 2010* – NeuroSearch (NEUR) informed today that the company will make a presentation at the Swedish-American Life Science Summit 2010 which will take place from 29 September – 1 October in Stockholm, Sweden.

The NeuroSearch presentation is scheduled for

**Thursday, 30 September at 10.00 am local time (04.00 am EST)**

and will be made by Hanne Leth Hillman, Vice President, Director of Investor & Capital Market Relations at the Ernst & Young Headquarters, Jakobsbergsgatan 24, Stockholm.

The related PowerPoint presentation will be available at www.neurosearch.com after the presentation has been made at the summit.

For more information, please visit www.swedishamericanlifescience.com.

**Contact person:**
Hanne Leth Hillman, Vice President, Director of Investor & Capital Market Relations, telephone: +45 4460 8212 or +45 4017 5103

**About NeuroSearch – Company profile**
NeuroSearch A/S is a leading CNS focused and Scandinavian based biopharmaceutical company listed on NASDAQ OMX Copenhagen (NEUR). The company's core business is development of novel drugs to treat diseases of the central nervous system, and the pipeline comprises eight products in clinical development (Phase I-III). These include Huntexil® (pridopidine), a unique orphan drug in Phase III development for the treatment of Huntington's disease, and tesofensine ready for Phase III development as a novel drug to treat obesity.

NeuroSearch is founded on a well-established drug discovery platform in the field of ion channels and monoamine transporters, ensuring the continuous production of novel preclinical development candidates. The company has strategic drug discovery and development alliances with Janssen Pharmaceutica and Eli Lilly as well as a licence collaboration with Abbott. Further, NeuroSearch has equity interests in a number of private companies in the Life Science industry.